Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2016

Conditions
Retinal Vein Occlusion
Interventions
DRUG

Bevacizumab

1.25 mg bevacizumab administered by monthly interval for six months (6 injections).

DRUG

Ranibizumab

0.5mg ranibizumab administered by monthly interval for six months (6 injections).

Trial Locations (1)

1105 AZ

RECRUITING

Academic Medical Center, Dept. Ophthalmology, Amsterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Leiden University Medical Center

OTHER

collaborator

Free University Medical Center

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Radboud University Medical Center

OTHER

collaborator

UMC Utrecht

OTHER

collaborator

University Medical Center Groningen

OTHER

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT01635803 - Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO) | Biotech Hunter | Biotech Hunter